Navigation Links
Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
Date:9/15/2009

BASKING RIDGE, N.J., Sept. 15 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that Chris Courts, Vice President, Finance, will be presenting at the BioPharm America Conference 2009 in San Francisco, CA at 3:15 on Thursday, September 17, 2009 (PST). Mr. Courts' presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1 is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention. REG2, Regado's second product candidate, consists of a
'/>"/>

SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
2. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
3. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Regado Biosciences Establishes Medical Advisory Board
8. Regado Biosciences Expands Medical Advisory Board
9. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
10. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
11. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), ... testing solutions for the detection of foodborne pathogens, ... months and full year ended December 31, 2014. ... the quarter ended December 31, 2014 was $1.4 ... of 2013 and $1.5 million for the third ...
(Date:3/26/2015)... CINCINNATI , March 26, 2015 ... SHPG ) and Cincinnati Children,s Hospital Medical Center ... rare diseases. The goal of the collaboration is to ... diseases with high unmet medical need combining Shire,s ... expertise. As a nationally ranked hospital, Cincinnati Children,s ...
(Date:3/26/2015)... 2015 Ale Gicqueau, Founder and President ... Clinical Affairs at Align Technology, on “ Conducting Postmarket ... ACRP 2015 Global Conference and Exhibition on April 25th ... , During the poster presentation, Ale Gicqueau and Victor ... a Postmarket Registry, the requirements and resources to conduct ...
(Date:3/25/2015)... -- Optimal Research, LLC has been nominated as a ... Clinical Site or Trial Network". This is ... as a nominee in this ViE award category at ... in 2014. The ViE awards were created to honor ... contributions of companies and individuals in the vaccine industry. ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2
... Former Pfizer executives to lead regulatory affairs group based in Ann ... ... 25 United BioSource Corporation,(UBC) today announced the expansion of its ... Lang, Dr PH. Based,in Ann Arbor, Michigan, the group will provide ...
... CRT-D and upgraded ... System, NATICK, Mass., Feb. 25 Boston Scientific,Corporation (NYSE: ... three products in its Cardiac Rhythm Management,business. They are:, ... helps protect patients at risk of sudden cardiac ...
... 25 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... first Phase 3 clinical trial with AZ-004 ... being developed for the treatment of,acute agitation ... Alexza,believes the novel, non-invasive nature and rapid ...
Cached Biology Technology:United BioSource Expands Regulatory Affairs Capabilities 2Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business 2Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business 3Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Biometrics - Global Strategic Business Report" report to their ... Iris Biometrics in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Latin America . Annual ...
(Date:3/17/2015)... 17, 2015  MecklerMedia Corporation (OTCQX: MECK) announced ... service robots ever held in New ... May 11-13, 2015 at the Javits Convention Center. ... event include: Acorn Product Development; Axis NJ; c-Link ... Robotics; Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; ...
(Date:3/12/2015)... VIEW, Calif. , March 12, 2015 /PRNewswire/ ... with Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: ... Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... in order to compete in several different markets ... market is currently witnessing an uptrend. ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... While hunting among chimpanzees is a group effort, key males, ... They are more likely to initiate a hunt, and hunts ... The findings, which appear in the current issue of ... cooperate to hunt for food, and how individual variation among ...
... computational approach could speed up the process and cut ... the University of Chicago Medical Center and Columbia University ... February 2008 issue of Genome Research, available early online. ... genes and proteins that serve as targets for nearly ...
... the University of Southern California have developed a prostate ... 90 percent of young mice genetically predestined to develop ... Cancer Research, they suggest the same strategy might work ... antigen), a potential diagnostic indicator of prostate cancer. ...
Cached Biology News:Key 'impact hunters' catalyze hunting among male chimpanzees 2Key 'impact hunters' catalyze hunting among male chimpanzees 3Study of successful drug targets could hasten development of new medications 2Study of successful drug targets could hasten development of new medications 3Prostate cancer: Watchful wait or vaccinate? 2Prostate cancer: Watchful wait or vaccinate? 3
Perm/Wash Buffer 250 Tests...
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
Request Info...
Raised to 5-HIAA coupled to BSA with paraformaldehyde....
Biology Products: